2018 | 2017 | 2016 | 2015 | 2014

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress

02/22/18

SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,

Read More

La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study

02/21/18

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for i

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts